The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

retatrutide

Triple GIP, GLP-1 and glucagon receptor agonist; phase 3 ongoing.

36 topics 12 solved Synonyms: reta Group: Compound

Related in this group: semaglutide · tirzepatide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

36 topics · page 2 of 2

TopicParticipantsRepliesViewsActivity
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
HASLFRGTSL+130 135 23k 16mo
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024) with SURMOUNT-OSA…
FHNSOFIG+106 113 4.8k 17mo
Biased agonism: a real phenomenon, an over-used explanation — what changed since
Biased agonism: a real phenomenon, an over-used explanation — what changed since — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I…
EKJHROKFEK+49 56 47k 17mo
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
OBLMJM 2 5.1k 20mo
About the Retatrutide category
Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
BNKCDTAMO 4 12k 2y
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
BRNKISTM+115 125 30k 2y